TVGN
Tevogen BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
A successful bolt-on acquisition (generics portfolio or clinical services) plus operational integration and early revenue realization drives re-rating toward specialty healthcare multiples; regained Nasdaq compliance removes structural liquidity overhang, enabling investor reappraisal.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Acquisition/integration failure or need for dilutive financing
Momentum
86
Value
42
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $15.00 · Bear $2.00
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-08 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $2.00
Why
Momentum86 · Δ7d -
Value42 · Δ7d -0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
86
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 86.1 / Value 41.7 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-08
Fundamentals (TTM)
As of 2026-06-08
Market Cap
$48.74M
Beta
-0.78
Shares Out
198.69M
P/E (TTM) · Derived
-3.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.01
Rev YoY
-
EPS YoY
+13.9%
Gross Margin
-
Op Margin
-
Net Debt
$1.37M
Current Ratio
0.31
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology